Rani Therapeutics Holdings, Inc. has announced a research agreement with Chugai Pharmaceutical Co., Ltd. to evaluate the potential of Rani’s oral delivery technology, specifically the RaniPill ...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

Rani Therapeutics, LLC - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of ...

Rani Therapeutics Hldgs (NASDAQ:RANI) has observed the following analyst ratings within the last quarter: According to 6 analyst offering 12-month price targets in the last 3 months, Rani ...

Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share. Unlock your all-in-one trading ...

March 22, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial ...

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...